: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer, June 2026
Free Subscription

Abstracts
Retrieve all available abstracts of the following 344 articles:
HTML format

Single Articles

LI Y, Ye F, Liu G, Cheng L, et al
Nano-armed bcg delivers Cu-Fe MOF to trigger dual cell death in bladder cancer.
J Nanobiotechnology. 2026 May 29. doi: 10.1186/s12951-026-04590.
PubMed
Abstract available

JUNG M, Park S, Jang I, Han D, et al
Ethnicity-specific molecular subtypes and a machine-learning risk model in Asian patients with non-muscle-invasive bladder cancer.
Sci Rep. 2026 May 29. doi: 10.1038/s41598-026-55438.
PubMed
Abstract available

ZHENG H, Tian Y, Cai Z, Huang G, et al
CircRNA-cZFR is upregulated in bladder cancer and promotes tumorigenesis via UBE2V1 regulation.
Sci Rep. 2026 May 29. doi: 10.1038/s41598-026-48969.
PubMed
Abstract available

GONTERO P, Perry R, Bridge D, Delattre DD, et al
Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus.
Eur Urol Oncol. 2026 May 29:S2588-9311(26)00134.
PubMed
Abstract available

NECCHI A, Brembilla G, Whiting K, Arita Y, et al
AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.
Eur Urol Oncol. 2026 May 29:S2588-9311(26)00133.
PubMed
Abstract available

PALERU G, Singathala GS, Kural S, Kumar L, et al
Emerging role of urinary biomarkers in bladder cancer diagnosis and prognosis.
Urol Oncol. 2026;44:70-81.
PubMed
Abstract available

ZHANG XW, Schlack K, Hartmann A, Steiner T, et al
Genitourinary Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2025: Advances in Renal Cell Carcinoma and Muscle-invasive Bladder Cancer.
Oncol Res Treat. 2026 May 29:1-8. doi: 10.1159/000552743.
PubMed
Abstract available

ZHAO L, Chen HM, Li YT, Zhang T, et al
Comparative efficacy and safety of open, laparoscopic, and robot-assisted radical cystectomy: a systematic review and network meta-analysis.
J Robot Surg. 2026;20:552.
PubMed
Abstract available

NASUTION RFG, Warli SM, Prapiska FF
Prognostic significance of pretreatment hydronephrosis in radiotherapy-based bladder-preserving strategies for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Arch Ital Urol Androl. 2026 May 29:14945. doi: 10.4081/aiua.2026.14945.
PubMed
Abstract available

TANG C, Liu Y, Wang TL, Ma J, et al
Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.
Hum Mutat. 2026;2026:2797474.
PubMed
Abstract available

LI C, Fang R, Wang J, Wang Y, et al
Urinary DNA methylation biomarkers for bladder cancer diagnosis: a single center case-control study.
Front Oncol. 2026;16:1812094.
PubMed
Abstract available

SAYGIN H, Bolat S, Kablan D, Yavuz H, et al
Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence.
Adv Urol. 2026;2026:6524384.
PubMed
Abstract available

Correction to "Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence".
Adv Urol. 2026;2026:9810919.
PubMed
Abstract available

CHEN IA, Luo HL, Chu CH, Yu CC, et al
Robotic versus laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: comparable oncologic outcomes with reduced intravesical recurrence in pathological T3 disease.
J Robot Surg. 2026;20:549.
PubMed
Abstract available

WEI W, Xiao X, Ren C, Zhang H, et al
Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer.
Cell Death Discov. 2026 May 28. doi: 10.1038/s41420-026-03182.
PubMed
Abstract available

ZHAO H, Liao J, Wing Sze HV, Liu K, et al
EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer.
Eur Urol Oncol. 2026 May 28:S2588-9311(26)00137.
PubMed
Abstract available

WANG M, Chen J, Wang C, He Y, et al
Progress in the application of combined detection of urinary tumor DNA and exosomes in the classification, staging, and clinical management of bladder cancer: a review.
Front Oncol. 2026;16:1745178.
PubMed
Abstract available

COSKUN A, Sahin AB, Kabul S, Dagtekin ME, et al
Prognostic significance of squamous differentiation in pT2N0 urothelial bladder cancer.
Oncol Lett. 2026;32:299.
PubMed
Abstract available

ZHAO X, Xu X
ARAF regulates malignant progression of bladder cancer through the p38MAPK pathway.
Open Med (Wars). 2026;21:20261422.
PubMed
Abstract available

CHANG Y, Sun N, Liu Y, Jin Z, et al
Lnc00892 enhances cisplatin sensitivity by inducing apoptosis through the BTAF1/MDM2/STAT5B/XIAP axis in bladder cancer cells.
Biol Direct. 2026 May 27. doi: 10.1186/s13062-026-00842.
PubMed
Abstract available

YIM W, Kang H, Kang BH, McGinnis ME, et al
Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.
Nat Nanotechnol. 2026 May 27. doi: 10.1038/s41565-026-02172.
PubMed
Abstract available

HONG X, Hong T, Liu X, Yao P, et al
UBE2C-Mediated CD147-CTLA-4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer.
Cancer Sci. 2026 May 27. doi: 10.1111/cas.70430.
PubMed
Abstract available

ZHANG N, Liang H, Wang L, Yang T, et al
[Investigating prognostic factors for T1 stage high-grade bladder cancer and developing a multi-marker risk prediction model using immunohistochemistry].
Zhonghua Wai Ke Za Zhi. 2026;64:768-777.
PubMed
Abstract available

ZHONG WL, Zheng HR, Lin TX
[Liquid biopsy empowers precision medicine across the full course of bladder cancer].
Zhonghua Wai Ke Za Zhi. 2026;64:695-700.
PubMed
Abstract available

HAYNE D, Zhang AY, Thomas H, Redfern AD, et al
Reply to Tonghu Liu's Letter to the Editor re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette Guerin-naive Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In p
Eur Urol Focus. 2026 May 27:S2405-4569(26)00088.
PubMed

LIU T, Zhu C, Yan Z
Re: Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. h
Eur Urol Focus. 2026 May 27:S2405-4569(26)00087.
PubMed

MAMTANI R, Squires P, Mojebi A, Hale B, et al
Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings.
Urol Oncol. 2026 May 27:S1078-1439(26)00495.
PubMed

MA M, Wu H, Zhu D, Sun P, et al
The Mechanistic Role of the lncRNA AC016876.2/miR-133a-3p/SPAG5 Axis in Regulating Autophagy and Malignant Behavior in Bladder Cancer Cells.
Tohoku J Exp Med. 2026 May 28. doi: 10.1620/tjem.2026.
PubMed

RAHMAN SN, Keervani K, Zhao X, Perry CJ, et al
Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.
Front Oncol. 2026;16:1807817.
PubMed
Abstract available

HUANG Z, Wang T, Xia W, Li Q, et al
[Retracted]Oblongifolin C reverses GEM resistance via suppressing autophagy flux in bladder cancer cells.
Exp Ther Med. 2026;32:186.
PubMed
Abstract available

SUN R, Li Y, Zuo L, Tao J, et al
[Myricetin inhibits proliferation and migration of bladder cancer cells by inhibiting HSP90AA1-mediated AKT phosphorylation].
Nan Fang Yi Ke Da Xue Xue Bao. 2026;46:1039-1052.
PubMed
Abstract available

GODLEWSKI D, Aebisher D, Bartusik-Aebisher D, Dynarowicz K, et al
Enhanced Imaging in Bladder Cancer: Fluorescence Cystoscopy and Molecular Diagnostics.
Life (Basel). 2026;16:828.
PubMed
Abstract available

SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
Systems Biology and Multi-Omics Determinants of Response to Bladder-Preserving Trimodality Therapy in Muscle-Invasive Bladder Cancer.
Life (Basel). 2026;16:826.
PubMed
Abstract available

KARAKAYALI A, Seyyar M, Sanci PC, Sahin E, et al
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.
Medicina (Kaunas). 2026;62:992.
PubMed
Abstract available

KIM KH, Kang BJ, Lee CH, Kim S, et al
Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette-Guerin Versus Gemcitabine in Treatment-Naive Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective Analysis.
J Clin Med. 2026;15:3890.
PubMed
Abstract available

KIM SH, Gudlavalleti H, Lerner SP
Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
J Clin Med. 2026;15:3830.
PubMed
Abstract available

UN S, Aydin VK, Kurt O, Lengerova G, et al
Time-Dependent Effects of Cisplatin on Autophagy Gene Expression in Bladder Cancer Cells.
Biomedicines. 2026;14:1006.
PubMed
Abstract available

LI W, Liu D, Yin Q, Geng Y, et al
Natural Products Targeting Acetylation in Bladder Cancer: Mechanistic Basis, Therapeutic Potential, and Future Perspectives.
Curr Issues Mol Biol. 2026;48:489.
PubMed
Abstract available

NEWMAN A, Hansel S, Gerrard G, Orton L, et al
Real-World Evaluation of Uromonitor((R)) for Bladder Cancer Detection and Surveillance.
Cancers (Basel). 2026;18:1650.
PubMed
Abstract available

MOHAMED NE, Berry DL, McReynolds J, Korn T, et al
Development and Evaluation of the Personal Patient Profile-Bladder Cancer (P3-BC): A Web-Based Decision Support System for Patients Considering Cystectomy and Urinary Diversion.
Cancers (Basel). 2026;18:1501.
PubMed
Abstract available

ZHENG L, Wang J, Han S, Zhong L, et al
Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.
J Exp Clin Cancer Res. 2026;45:128.
PubMed

RAMMANT E, Fox L, De Padova S, Liedberg F, et al
Update of the EORTC Health-related Quality of Life Modules for Bladder Cancer: Phase 1-2 of the Development Process.
Eur Urol Oncol. 2026 May 26:S2588-9311(26)00125.
PubMed
Abstract available

KAYAR K, Kayar R, Ozdemir BB, Karabay E, et al
Urinary pH and oncologic outcomes after bacillus calmette-guerin in non-muscle invasive bladder cancer: a retrospective cohort study.
Actas Urol Esp (Engl Ed). 2026 May 25:501995. doi: 10.1016/j.acuroe.2026.501995.
PubMed
Abstract available

CARLSEN B, Klingen TA, Andreassen BK, Beisland C, et al
Tumor cell invasion in blood vessels but not lymphatic vessels in TURBT predicts poor prognosis in bladder cancer.
Urol Oncol. 2026;44:26-35.
PubMed
Abstract available

CHEN J, Ding Z, Lai S, Gan Z, et al
Nanoparticles-mediated dual metabolic-immunological intervention reverses immunosuppression in muscle invasive bladder cancer.
Biomaterials. 2026;335:124335.
PubMed
Abstract available

MOFID B, Jafari A, Simforoosh N, Basiri A, et al
Bladder-sparing chemoradiotherapy following neoadjuvant chemotherapy for muscle-invasive bladder cancer: a retrospective cohort study.
BMC Urol. 2026 May 25. doi: 10.1186/s12894-026-02187.
PubMed
Abstract available

AIZEZI X, Silafu B, Shi H, Huang J, et al
Multi-omics analysis reveals TM4SF19 as a diagnostic and prognostic biomarker in bladder cancer.
Discov Oncol. 2026 May 25. doi: 10.1007/s12672-026-05304.
PubMed
Abstract available

OZALP FR, Ellez HI, Arslan AM, Demirciler E, et al
Integrative in silico transcriptomic and pharmacogenomic analysis of CD276 as a candidate prognostic biomarker and therapeutic target in bladder cancer.
Discov Oncol. 2026 May 25. doi: 10.1007/s12672-026-05310.
PubMed
Abstract available

CAMPO-PEREZ V, Guallar-Garrido S, Cabrera-Rubio R, Herrero-Abadia P, et al
Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model.
NPJ Biofilms Microbiomes. 2026 May 25. doi: 10.1038/s41522-026-01002.
PubMed
Abstract available

ZHU C, Lu J, Zhu B, Liu B, et al
ATP13A2 promoted cell stemness, cisplatin resistance, autophagy, and cell progression of bladder cancer.
Front Immunol. 2026;17:1743064.
PubMed
Abstract available

XU Y, Zhao C, Fu S, Wu Y, et al
Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.
Mater Today Bio. 2026;38:103222.
PubMed
Abstract available

HU K, Luo L, Li P, Wang X, et al
Fibrinogen-like protein 1 induces the formation of an immunosuppressive microenvironment by upregulating fibronectin 1 to promote immune evasion in bladder cancer.
Cytojournal. 2026;23:25.
PubMed
Abstract available

CHEN L, Hang G, Wen Q, Ren L, et al
Application and challenges of smart responsive multifunctional nanoplatforms in integrated diagnosis and treatment of bladder cancer and overcoming therapeutic resistance.
Front Oncol. 2026;16:1803259.
PubMed
Abstract available

LI Z, Zhong H, Baptista-Hon D, Qiu J, et al
JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study.
Precis Clin Med. 2026;9:pbag012.
PubMed
Abstract available

HAYASHI J, Sugimoto K, Kochi S, Toake M, et al
[A Case of Locally Advanced Colorectal Cancer with Severe Bladder Invasion Successfully Treated with Preoperative Chemotherapy with Anti-EGFR Antibody and Avoiding Total Bladder Resection].
Gan To Kagaku Ryoho. 2026;53:307-309.
PubMed
Abstract available

SHORE ND, Powles TB, Bedke J, Galsky MD, et al
Sasanlimab taken together with Bacillus Calmette-Guerin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.
Future Oncol. 2026 May 24:1-13. doi: 10.1080/14796694.2026.2671256.
PubMed

WEN J, Wei L, Huang J, Zhou L, et al
Yeast surface display-based screening and preliminary characterization of nectin-4-targeting nanobodies for bladder cancer.
BMC Biotechnol. 2026 May 23. doi: 10.1186/s12896-026-01170.
PubMed
Abstract available

DUCCI G, Ciufolini G, Campioni G, Pasquale V, et al
FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.
Commun Biol. 2026 May 23. doi: 10.1038/s42003-026-10356.
PubMed
Abstract available

ELAVARASU SM, Asheem I, M N, S UK, et al
Transcriptomic insights into epigenetic and immunomodulatory roles of nuclear histone genes in bladder cancer: A bioinformatics approach.
Adv Protein Chem Struct Biol. 2026;152:77-101.
PubMed
Abstract available

KOBYLKA P, Murias M, Bakun P, Goslinski T, et al
Cellular responses to morpholinated curcumin derivatives in human muscle-invasive bladder cancer cells.
Toxicol In Vitro. 2026;115:106251.
PubMed
Abstract available

SUN Z, Liu J, Fang Y, Ma L, et al
Ferritin-Based Mild Magnetic Hyperthermia Therapy for Bladder Cancer: A Synergistic Anti-Inflammatory Strategy.
ACS Nano. 2026 May 23. doi: 10.1021/acsnano.6c00407.
PubMed
Abstract available

WANG M, Jia K, Wang Y, Yuan D, et al
The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and cancer-specific survival of major urological cancers: An observational study.
Medicine (Baltimore). 2026;105:e48966.
PubMed
Abstract available

PRADHAN B, Mishra P, Dash P, Niharika, et al
Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions.
Urol Oncol. 2026 May 22:S1078-1439(26)00498.
PubMed
Abstract available

WANG S, Tang Y, Xu Y, Wang Y, et al
Discovery of NMP22-Targeting Aptamers for Point-of-Need Test of Bladder Cancer.
Anal Chem. 2026 May 22. doi: 10.1021/acs.analchem.6c00738.
PubMed
Abstract available

ZHANG M, Liu H, Zhang Y, Zhu Z, et al
HIV-related bladder cancer: A ten-year experience.
Int J STD AIDS. 2026 May 22:9564624261449133. doi: 10.1177/09564624261449133.
PubMed
Abstract available

MIYAKE M, Minegishi T, Aikawa T, Fukasawa T, et al
Real-world perioperative systemic treatment patterns and outcomes in patients with urothelial carcinoma undergoing radical surgery.
Cancer Treat Res Commun. 2026;47:101241.
PubMed
Abstract available

MUSANGILE FY, Matsuzaki I, Nishikawa T, Kojima F, et al
Precursor flat urothelial lesions: Molecular landscape, pathogenesis, and biological insights.
Pathol Res Pract. 2026;284:156517.
PubMed
Abstract available

BONNI S, Ramnath NWM, Selten K, Moza A, et al
Bacillus Calmette-Guerin-Related Mycotic Pseudoaneurysm in the Aortic Arch: Clinical and Operative Challenges.
Interdiscip Cardiovasc Thorac Surg. 2026;41:ivag120.
PubMed
Abstract available

NIWA K, Iinuma K, Nakano M, Tomioka M, et al
Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.
Int J Clin Oncol. 2026;31:1008-1016.
PubMed
Abstract available

MORRIS G, Vlachostergios PJ, Rai MP, Scherr D, et al
19q13 amplification with AKT2 and ERCC2 gains in sarcomatoid carcinoma of the urinary bladder.
Cancer Genet. 2026;304-305:51-57.
PubMed
Abstract available

JAN HC, Su YC, Huang SK, Wang CA, et al
HDAC4 overexpression predicts aggressive phenotypes and poor outcomes in urothelial carcinoma.
Cancer Treat Res Commun. 2026;47:101148.
PubMed
Abstract available

QIN X, Zheng B, Liu D, Quan X, et al
A 'two-in-one' tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues.
J Nanobiotechnology. 2026;24:502.
PubMed
Abstract available

CHOI SH, Kim JK, Kim SH, Ryu MO, et al
Recurrent pyuria is associated with shorter progression-free survival in dogs with bladder urothelial carcinoma.
Am J Vet Res. 2026;87:ajvr.
PubMed
Abstract available

WANG Y, An S, Min Y
Crocin-coated zinc-alginate-PEG nanocomposite induces ROS-mediated apoptosis via PI3K/Akt/mTOR suppression in bladder cancer cells.
3 Biotech. 2026;16:248.
PubMed
Abstract available

YILMAZ B, Ataman M, Tuna A
Detection of microplastics in bladder wash fluid obtained after cystoscopy in patients diagnosed with bladder cancer.
Front Public Health. 2026;14:1812477.
PubMed
Abstract available

HE Y, Fang Z, Zhang J, Wei Q, et al
Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy.
Theranostics. 2026;16:6827-6842.
PubMed
Abstract available

BELLMUNT J, Xie Y, Juanpere N, Munoz MG, et al
Epigenetic subtypes of high-grade T1 bladder cancer reveal intra-tumor heterogeneity and distinct interactions with tumor microenvironment.
Theranostics. 2026;16:6892-6910.
PubMed
Abstract available

LIU J, Li B, Hou R, Sun J, et al
A five-gene mitochondria-associated prognostic signature for bladder cancer.
Int J Clin Exp Pathol. 2026;19:192-208.
PubMed
Abstract available

YUAN H, Wang T, Peng P, Xu Z, et al
Corrigendum to "Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment" [Clinical Genitourinary Cancer 22/2 (2024) 569-579.e1].
Clin Genitourin Cancer. 2026 Jun 4:102584. doi: 10.1016/j.clgc.2026.102584.
PubMed

PALMBOS P, Kelleher A, Henderson M, Broses L, et al
TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.
Res Sq [Preprint]. 2026 May 20:rs.3.rs-9214925. doi: 10.21203/rs.3.rs-9214925.
PubMed
Abstract available

YIM K, Vergara M, Lee J, Reardon B, et al
Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.
bioRxiv [Preprint]. 2026 May 18:2026.05.10.724123.
PubMed
Abstract available

FINI MS, Alley JR, Vensko SP, Karthikeyan D, et al
Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy.
bioRxiv [Preprint]. 2026 May 27:2026.05.20.726664.
PubMed
Abstract available

HUANG Z, Yan Y, Wang X, Li H, et al
Tumor-derived WNT7A reprograms pulmonary fibroblasts to remodel the metastatic niche and promote bladder cancer lung metastasis.
Exp Mol Med. 2026 Jun 3. doi: 10.1038/s12276-026-01735.
PubMed
Abstract available

MACDONALD LP, Kypriotakis G, Karam-Hage M, Minnix JA, et al
Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer.
Eur Urol Oncol. 2026 Jun 3:S2588-9311(26)00131-8. doi: 10.1016/j.euo.2026.
PubMed
Abstract available

DIAZ GM, Isali I, Davis L, Wang B, et al
Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.
Clin Genitourin Cancer. 2026 May 6:102578. doi: 10.1016/j.clgc.2026.102578.
PubMed
Abstract available

MUNK L, Kumarasegaram V, Hyldgaard JM, Jensen JB, et al
Collecting electronic patient-reported outcomes via smartphone text messages in a bladder cancer RCT: A feasibility study.
Urol Oncol. 2026;44:101-107.
PubMed
Abstract available

ZHANG XJ, Yu HY, Cai YJ, Ke M, et al
Retraction: Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway.
Oncotarget. 2026;17:193-194.
PubMed

HUANG J, Luo H, Du C, Zhai Q, et al
Antibody-drug conjugate therapy in a renal transplant patient with bladder cancer: A case report.
Clin Nephrol. 2026 Jun 3. doi: 10.5414/CN111972.
PubMed
Abstract available

LIU Z, Yao Z, Hou Y, Liu Z, et al
LGALS1-CD276 Paracrine axis between tumor and endothelial cells promotes tumor angiogenesis and progression in bladder cancer.
Cell Death Differ. 2026 Jun 2. doi: 10.1038/s41418-026-01777.
PubMed
Abstract available

PINTON P, Kawano H, Patschan O, Ravi A, et al
A machine-learning approach to predict additional treatment after Bacillus Calmette-Guerin induction in non-muscle-invasive bladder cancer.
Sci Rep. 2026 Jun 2. doi: 10.1038/s41598-026-55917.
PubMed
Abstract available

LUO Y, Ma J, Wang C, Xiong W, et al
ELK1-YBX1 signaling promotes cisplatin resistance via ferroptosis adaptation in bladder cancer.
Cell Signal. 2026 Jun 1:112633. doi: 10.1016/j.cellsig.2026.112633.
PubMed
Abstract available

NARAYAN A, Leibrandt RC, Lee JS, Dall'Era MA, et al
A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.
Nanomedicine (Lond). 2026 Jun 1:1-6. doi: 10.1080/17435889.2026.2674162.
PubMed
Abstract available

NIKOLAUS Y
p40-positive metastatic urothelial carcinoma mimicking primary pulmonary squamous cell carcinoma on limited lung biopsy.
BMJ Case Rep. 2026;19:e272914.
PubMed
Abstract available

YANG H, Zhou C, Zhou Z, Zhang F, et al
YBX1 takes actions on triggering M2-like polarization of macrophages and stabilizing CXCL8 mRNA to exhibit its metastatic potential in bladder cancer.
Int Immunopharmacol. 2026;184:116911.
PubMed
Abstract available

KOHLER J, Buck L, Schliesser P, Weische O, et al
Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients.
Urol Oncol. 2026;44:92-100.
PubMed
Abstract available

FU L, Huang B, Shi L, Geng Y, et al
DS-MTNet: A dual-stream multi-task network for histopathology localization and histologic risk stratification from small biopsy specimens of bladder cancer.
Comput Methods Programs Biomed. 2026;284:109464.
PubMed
Abstract available

ZHANG W, Wu H, Wang L, Xu H, et al
Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
JAMA Netw Open. 2026;9:e2614764.
PubMed
Abstract available

ZHANG Y, Li R, Shi H, Zhao A, et al
ASO Author Reflections: Benchmarking Large Language Models for Bladder Cancer: Comparative Knowledge Retrieval and Clinical Reasoning of DeepSeek and ChatGPT.
Ann Surg Oncol. 2026 Jun 1. doi: 10.1245/s10434-026-19845.
PubMed

CHEN L, Cao X, Lu Z, Liu L, et al
Artificial intelligence-assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma.
Cancer Cytopathol. 2026;134:e70120.
PubMed
Abstract available

JIAO B, Xu Y, Wang X, Zhang H, et al
Biomimetic Nanoparticles Based on Tumor Cell Membrane Co-loaded with Vitamin E and Doxorubicin for Targeted Synergistic Treatment of Bladder Cancer.
ACS Appl Bio Mater. 2026 Jun 1. doi: 10.1021/acsabm.6c00552.
PubMed
Abstract available

BOYNE A, Anderson RC, Liu D, Varghese B, et al
Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis.
Bladder Cancer. 2026;12:23523735261455396.
PubMed
Abstract available

BOLT MJ, Oceguera J, Tostado AR, Candler CD, et al
A phenotypic screen identifies xanthohumol and other flavonoids as killers of bladder cancer.
Pharmacol Res Nat Prod. 2025;7:100236.
PubMed
Abstract available

SELVARAJU A, Dwivedi DK, Patbamniya NK, Kumar M, et al
Multiparametric MRI Radiomics for the Prediction of Histologic Grade in Bladder Cancer.
Indian J Surg Oncol. 2026;17:1057-1064.
PubMed
Abstract available

FERNANDES C, Brito C, Ferreira C, Botelho F, et al
Ensuring Timely Detection of Bladder Cancer: The Role of a Screening for Haematuria Consultations.
Indian J Surg Oncol. 2026;17:964-969.
PubMed
Abstract available

YANG J, You Z, Mo H, Pu J, et al
Identification of succinylation-related genes in bladder cancer: integration of single-cell and transcriptomic data.
Front Immunol. 2026;17:1797389.
PubMed
Abstract available

HANSEN MS, Dyrskjot L, Heide-Jorgensen U, Jensen JB, et al
Aspirin or non-steroidal anti-inflammatory drug initiation and subsequent bladder cancer evaluation.
J Intern Med. 2026 Jun 1. doi: 10.1111/joim.70115.
PubMed
Abstract available

ICHIYAMA T, Narita T, Sekine Y, Shinohara M, et al
Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.
Jpn J Clin Oncol. 2026 May 31:hyag087. doi: 10.1093.
PubMed
Abstract available

GUTTI JR, Clarke DM, Saba C, Nagata K, et al
Incorporating Hypofractionated Radiotherapy Improves Management of Canine Urothelial Carcinoma: A Retrospective Study.
Vet Radiol Ultrasound. 2026;67:e70196.
PubMed
Abstract available

ABOU CHAKRA M, Duquesne I, O'Donnell MA
Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.
Front Biosci (Landmark Ed). 2026;31:47606.
PubMed
Abstract available

GUPTA A, Chandra S, Verma T, Gupta A, et al
The Paris System for Urine Cytology: Prospective Assessment of Reproducibility, Diagnostic Accuracy, and Malignancy Risk.
Diagn Cytopathol. 2026;54:506-518.
PubMed
Abstract available

MACH KE, Kornberg Z, Shkolyar E, Long J, et al
Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance.
J Clin Invest. 2026;136:e203094.
PubMed
Abstract available

LEFRANC R, Mathieu C, Ghorbel A, Leger-Vigot A, et al
Consolidative cystectomy after complete response to enfortumab vedotin plus pembrolizumab in metastatic bladder cancer: a case report.
J Surg Case Rep. 2026;2026:rjag435.
PubMed
Abstract available

ERNANDEZ J, Xiang L, Adler R, Hsu J, et al
Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.
medRxiv [Preprint]. 2026 Jun 6:2026.06.04.26354768.
PubMed
Abstract available

YAP M, Mihai IM, Alanazi MAA, Olteanu GE, et al
Automated H-Scoring in Muscle-Invasive Bladder Cancer IHC: An Internal Validation Study.
Diagnostics (Basel). 2026;16:1673.
PubMed
Abstract available

HJORT PB, Skovhus K, Jensen JB, Ernst A, et al
Study of Bladder Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02 (RAISE-02)-A Randomized Controlled Non-Inferiority Trial.
Cancers (Basel). 2026;18:1739.
PubMed
Abstract available

CERIA F, Muhammad G, Del Giudice F, Ibrahim Y, et al
Expect the Unexpected: Frequency, Predictors, and Survival Impact of Pathological Upstaging from Non-Muscle-Invasive to Muscle-Invasive Bladder Cancer Following Radical Cystectomy.
Cancers (Basel). 2026;18:1733.
PubMed
Abstract available

SHAH KU, Castro DV, Li X, Zugman M, et al
Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability.
Cancers (Basel). 2026;18:1730.
PubMed
Abstract available

ZHU J, Wang A, Tong H, Sun Y, et al
Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway.
Cancers (Basel). 2026;18:1713.
PubMed
Abstract available

DEGIRMENCI E, Sanli O, Kaytaz M, Kucukgergin C, et al
ZEB1-AS1 and miR-200b-3p Expression in Non-Muscle-Invasive Bladder Cancer: Pathological Correlates.
J Clin Med. 2026;15:4182.
PubMed
Abstract available

SKOVHUS K, Kristensen P, Sindberg DB, Orum M, et al
Preoperative Frailty Assessed by the Record-Based Multidimensional Prognostic Index Predicts 90-Day Days Alive and out of Hospital Following Radical Cystectomy for Bladder Cancer: A Retrospective Cohort Study.
J Clin Med. 2026;15:4057.
PubMed
Abstract available

ANTONOV P, Raycheva G, Eshrefov D, Belov A, et al
FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis.
Int J Mol Sci. 2026;27:5007.
PubMed
Abstract available

CHEN C, Tan Z, Cai L, Chen H, et al
MRI-based deep learning combined with radiomics for the preoperative prediction of lymphovascular invasion in patients with bladder cancer.
Cancer Imaging. 2026 Jun 11. doi: 10.1186/s40644-026-01070.
PubMed
Abstract available

RESEARCH INTERNATIONAL B
RETRACTION: Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer.
Biomed Res Int. 2026;2026:e9864535.
PubMed

MUSONE M, Barone B, Chianese S, Conforti P, et al
Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer.
Oncol Ther. 2026 Jun 11. doi: 10.1007/s40487-026-00445.
PubMed
Abstract available

SIVA J, Jonnalagadda R, Aydogdu C, Diaz GM, et al
External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification Model.
Eur Urol Oncol. 2026 Jun 11:S2588-9311(26)00157.
PubMed
Abstract available

KAGENAAR E, Lugo-Palacios DG, Bromley H, Aggarwal A, et al
Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer.
BMJ Open. 2026;16:e119596.
PubMed
Abstract available

HE Y, Xie W, Chen W, Dai S, et al
Urine IRF4/PENK/PXDN Methylation Signatures Enable Machine Learning-Driven Bladder Cancer Detection and Microenvironment Dissection.
Technol Cancer Res Treat. 2026;25:15330338261453486.
PubMed
Abstract available

IDIARTE JF, Canclini L, Alem D, Garcia-Lavina CX, et al
Violacein as a multitarget agent in bladder cancer cells.
J Proteomics. 2026 Jun 11:105697. doi: 10.1016/j.jprot.2026.105697.
PubMed
Abstract available

ZENG Y, Gu G, Yang L, Fan B, et al
Ketogenic Diet and beta-Hydroxybutyrate Suppress Bladder Cancer Growth and Enhance Anti-PD-L1 Immunotherapy Efficacy.
Cancer Sci. 2026 Jun 11. doi: 10.1111/cas.70447.
PubMed
Abstract available

MAISCH P, Hamidi Madani M, Koziarz A, Narayan VM, et al
Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
Cochrane Database Syst Rev. 2026;6:CD013776.
PubMed
Abstract available

Nodal Regulates Bladder Cancer Cell Migration and Invasion via the ALK/Smad Signaling Pathway [Retraction].
Onco Targets Ther. 2026;19:629839.
PubMed
Abstract available

LIAO J, Li X, Li G
Comparative efficacy and safety of carboplatin-based versus cisplatin-based chemotherapy in muscle-invasive and advanced bladder cancer: A systematic review and meta-analysis.
Eur J Clin Pharmacol. 2026;82:168.
PubMed
Abstract available

SANTARELLI V, Asero V, Corvino R, De Berardinis E, et al
Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomes.
World J Urol. 2026;44:419.
PubMed
Abstract available

PAN Y, Sun Y, Jiao B, Zhang Y, et al
The international and domestic research trends of targeted therapy in bladder cancer: a bibliometric analysis of the past three decades.
Front Oncol. 2026;16:1850175.
PubMed
Abstract available

DENG C, Soivong P, Akkadechanunt T, Sethabouppha H, et al
Self-Management Experience of Chinese Patients With Nonmuscle-Invasive Bladder Cancer During Intravesical Therapy: A Qualitative Study.
Cancer Nurs. 2026 May 28. doi: 10.1097/NCC.0000000000001598.
PubMed
Abstract available

LIU F, Hu X, Zhu X, Han T, et al
A Retrospective Follow-up Study on the Effects of Different Intravesical Treatments on Recurrence Control and Quality of Life in Patients With Non-Muscle-Invasive Bladder Cancer After Transurethral Resection of Bladder Tumour.
Arch Esp Urol. 2026;79:632-640.
PubMed
Abstract available

YAN D, Zhu W, Tao Y, Huang L, et al
ZRANB1 promotes cell proliferation and lymph node metastasis through SF3B3-mediated alternative splicing of CHEK2 in urothelial bladder cancer.
Cell Death Dis. 2026 Jun 9. doi: 10.1038/s41419-026-08964.
PubMed
Abstract available

SQUIRES P, Meng K, Hu X, Turzhitsky V, et al
Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
Oncol Ther. 2026 Jun 9. doi: 10.1007/s40487-026-00451.
PubMed

HUANG S, Zhou Z, Xie Q, Wang Z, et al
KRT14 Drives Basal Muscle-Invasive Bladder Cancer Progression and Lung Metastasis by Directly Binding to and Stabilizing IGF2BP1.
Adv Sci (Weinh). 2026 Jun 9:e75900. doi: 10.1002/advs.75900.
PubMed
Abstract available

ALASKER A, Alghafees M, Nammor T, Alanazi N, et al
Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances.
BMC Urol. 2026 Jun 8. doi: 10.1186/s12894-026-02209.
PubMed
Abstract available

PENG J, Zhu Q, Li S, Xiang B, et al
Cis-3-hexen-1-ol suppresses bladder cancer progression by inducing mitophagy via the PCK2/AMPK/mTOR signaling pathway.
Cell Oncol (Dordr). 2026 Jun 8. doi: 10.1007/s13402-026-01233.
PubMed
Abstract available

NUSRAT NB, Imtiaz S, Aslam A, Rehman AU, et al
Clinical and pathological factors associated with recurrence after radical cystectomy for bladder cancer: A single-center retrospective study.
Pak J Med Sci. 2026;42:932-937.
PubMed
Abstract available

MALIK T, Denfhy J, Theinkha Lin H, Mohammed L, et al
Multicentre real-world evaluation of the Haematuria Cancer Risk Score to risk-stratify the detection of bladder cancer in patients referred from primary care.
BJUI Compass. 2026;7:e70233.
PubMed
Abstract available

DA ANUNCIACAO KF, Roquete Amparo T, Dutra Sousa LR, Xavier VF, et al
Mucoadhesive Nanoemulsion Enhances the Antineoplastic Potential of Naringenin in Bladder Cancer Cell Lines.
ACS Omega. 2026;11:30606-30616.
PubMed
Abstract available

LYU G, Li D
Unraveling the Role of miR-33a-5p in Bladder Cancer Progression: Clinical Significance and Functional Pathways.
Comb Chem High Throughput Screen. 2026.
PubMed
Abstract available

FENG W, He W
Integrative multi-omics identifies a glycosylation-based prognostic framework and nominates ALG3 for targeted therapy in bladder cancer.
Discov Oncol. 2026 Jun 7. doi: 10.1007/s12672-026-05387.
PubMed
Abstract available

HU D, Shen C, Liu C, Xie F, et al
NOTCH3 regulates myofibroblastic CAF differentiation via the P62-ROS signaling axis to promote bladder cancer progression.
J Exp Clin Cancer Res. 2026 Jun 6. doi: 10.1186/s13046-026-03751.
PubMed
Abstract available

ZHAO H, Li K, Xu H, Liao J, et al
Multi-dimensional profiling of lactylation-related signatures for prognostic and therapeutic insights in bladder cancer.
Cancer Cell Int. 2026 Jun 6. doi: 10.1186/s12935-026-04364.
PubMed
Abstract available

PETIX M, Polverino F, Quarta L, Filzmayer M, et al
Effect of marital status on years of life lost from metastatic bladder cancer according to sex and race/ethnicity.
Urol Oncol. 2026;44:132-137.
PubMed
Abstract available

SYED P, Islam MK, Kekki H, Terava J, et al
Glycovariant-based diagnosis of bladder cancer using urinary mucin 1 and carcinoembryonic antigen.
J Pharm Biomed Anal. 2026;280:117589.
PubMed
Abstract available

DU R, Yu Z, Liu D
Nanosensor-coated catheters for bladder cancer detection.
Nat Nanotechnol. 2026 Jun 5. doi: 10.1038/s41565-026-02173.
PubMed

TOUMA SAWAYA R, Nasrallah O, El Hajj A, Abdessater M, et al
Impact of CKD on perioperative outcomes following TURBT: a national NSQIP analysis.
World J Urol. 2026;44:411.
PubMed
Abstract available

YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer.
Urol Oncol. 2026;44:120-126.
PubMed
Abstract available

SUGAHARA D, Murofushi KN, Yamashita H, Ogo E, et al
Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan.
Jpn J Clin Oncol. 2026 Jun 5:hyag063. doi: 10.1093.
PubMed
Abstract available

JOHNSON M, Clark M, Whittington C, Newton E, et al
Adverse dermatologic effects of erdafitinib in a patient with metastatic urothelial carcinoma.
Dermatol Online J. 2026;32.
PubMed
Abstract available

SAKAI T, Abe T, Mizuno R, Izumi H, et al
[LYMPH NODE TUBERCULOSIS AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR BLADDER CARCINOMA IN SITU : A CASE REPORT].
Hinyokika Kiyo. 2026;72:171-176.
PubMed
Abstract available

MANGOLD MH, Egen L, Carl N, Renner LV, et al
Radical cystectomy in octogenarians: a propensity score-matched analysis of short-term outcomes.
World J Urol. 2026;44:405.
PubMed
Abstract available

PALAGAN SENOPATI S, Willy Moris N, I Made K, Ida Bagus Oka W, et al
A Case of Urothelial Carcinoma in Situ of the Bladder in Local Dog in Bali, Indonesia.
Arch Razi Inst. 2025;80:1345-1352.
PubMed
Abstract available

METWALLY S, Gil D, Smialek-Bartyzel J, Pabijan J, et al
Matrix Mechanics Governs Mechano-Metabolic Adaptation across Cancer Grades in Bladder Spheroids.
ACS Appl Mater Interfaces. 2026;18:30775-30789.
PubMed
Abstract available

KAN H, Chen M, Hu W, Yang N, et al
Exploring a critical time window for FOXM1-driven bladder injury in chronic arsenic exposure.
Ecotoxicol Environ Saf. 2026;319:120312.
PubMed
Abstract available

WHITE RE, Linscott JA, Pelletier C, Santos E, et al
Optimizing radical cystectomy recovery: The role of modified ERAS in improving postoperative outcomes.
Urol Oncol. 2026;44:316-322.
PubMed
Abstract available

PADICKAKUDY R, Rosa de Pauli L
[Reconstructive aspects of radical cystectomy with orthotopic bladder replacement].
Wien Med Wochenschr. 2026;176.
PubMed
Abstract available

SU X, Duan X, Bai S, Su P, et al
Cellular origins and etiological factors for squamous cell carcinoma and related cancer types of the bladder.
J Pathol. 2026;269:297-313.
PubMed
Abstract available

ZHANG B, Li S, Lv C, Wang W, et al
True Positive 18F-FDG PET/CT and Negative 123I-MIBG SPECT/CT in a Pediatric Patient With Bladder Malignant Paraganglioma.
Clin Nucl Med. 2026 Mar 31. doi: 10.1097/RLU.0000000000006377.
PubMed
Abstract available

ZHENG K, Liu Y, Wang Y, Jing H, et al
An Asymptomatic Urachal Mucinous Adenocarcinoma on FDG PET/CT.
Clin Nucl Med. 2026 Mar 25. doi: 10.1097/RLU.0000000000006357.
PubMed
Abstract available

EICHENAUER R, Johannsen M, Klier J, Konig F, et al
[Current Data from the National Registry for Urothelial Cancer (UroNAT) by d-uo].
Aktuelle Urol. 2026;57:266-269.
PubMed
Abstract available

FREDERIC J, Oladoyin V, Geetha J, Muhammad A, et al
Primary Enteric-type adenocarcinoma of the bladder managed with colon-type chemotherapy: A rare case and literature review.
J Natl Med Assoc. 2026;118:442-445.
PubMed
Abstract available

MAN X, Dong C, Dong A, Song X, et al
FDG PET/CT in a Case of Inflammatory Myofibroblastic Tumor of the Bladder.
Clin Nucl Med. 2026 Feb 13. doi: 10.1097/RLU.0000000000006381.
PubMed
Abstract available

MARTINEZ RODRIGUEZ P, Poza Fernandez A, Garcia Fadrique G, Acedo Gonzalez J, et al
Bladder and rectal cancer development in prostate cancer patients treated with surgery or radiotherapy: A population-based study.
Actas Urol Esp (Engl Ed). 2026;50:501928.
PubMed
Abstract available

BENLIOGLU C, Kalyenci B, Yucel MO, Cift A, et al
A Intravesical Brucella Abortus S19 (BAS19) Vaccine As A Potential Alternative To Bacillus Calmette-Guerin (BCG) Immunotherapy: A Preclinical Study In Rats.
Urol J. 2026;23:12-20.
PubMed
Abstract available

GOMEZ DEL CANIZO C, Fernandez Sanchez N, Gonzalez Ginel I, Hernandez Arroyo M, et al
The use of presurgical urine cytology improves patient selection for a single instillation of MMC.
Actas Urol Esp (Engl Ed). 2026;50:501904.
PubMed
Abstract available

AYTEN A, Ceylan H, Kinik AH, Gelmis M, et al
Is the Modified Frailty Index-5 a reliable predictor of postoperative morbidity in elderly radical cystectomy patients? A comparative study with CCI and G8.
Actas Urol Esp (Engl Ed). 2026;50:501902.
PubMed
Abstract available

YI LIN LEE MC, Camargo JA, Caetano Vilas Boas G, Silva KS, et al
CRISPR/Cas9-mediated miR-21 editing in high-grade urothelial carcinoma cells and its biological effects.
Mol Biol Rep. 2026;53:973.
PubMed
Abstract available

SONG W, Han G, Li Z, Hu J, et al
Single-cell transcriptomics identifies key immune-suppressive cells and their driver genes in the bladder cancer microenvironment with prognostic implications.
Mol Genet Genomics. 2026;301:142.
PubMed
Abstract available

HE YB, Hu J, Liu Z, Xiao ZC, et al
Non-invasive evaluation of muscle invasion and survival prognosis in bladder cancer using enhanced CT-based deep learning radiomics: a multi-center real-world cohort study.
Mil Med Res. 2026;13:100001.
PubMed
Abstract available

KOTOLLOSHI R, Berndt-Paetz M, Lerner E, Najjar G, et al
ZW4864-mediated inhibition of the beta-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer.
Mol Oncol. 2026 Jun 18. doi: 10.1002/1878-0261.70292.
PubMed
Abstract available

LEI D, Wu JH, Zeng XH, Xu R, et al
Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis.
Urol Oncol. 2026;44:182-194.
PubMed
Abstract available

MUDRAK DA, Ankudavichus VA, Mylnikov AM, Vrabie EE, et al
[Low-grade urothelial carcinoma of the bladder with osteoclast-like differentiation as part of primary multiple malignancies. Case report and literature review].
Arkh Patol. 2026;88:47-53.
PubMed
Abstract available

GU Z, Zhu H, Zhang Y, Jiang J, et al
Harnessing a cRGD-Targeted Schottky Junction MXene Nanocomposite for Potent Bladder Cancer Therapy: Dual-Modal PTT/PDT Effects with Immune Activation and Favorable Comparison to Doxorubicin.
Int J Nanomedicine. 2026;21:597220.
PubMed
Abstract available

MORIWAKE T, Tominaga Y, Ozaki N, Matsumoto Y, et al
Transcystostomal Bladder Tumor Resection in a Transgender Man After Phalloplasty.
Asian J Endosc Surg. 2026;19:e70330.
PubMed
Abstract available

HUANG L, Li H
Steroidogenesis is associated with bladder cancer progression via reprogramming the metabolic landscape of the tumor immune microenvironment.
Discov Oncol. 2026 Jun 17. doi: 10.1007/s12672-026-05445.
PubMed
Abstract available

JOKELAINEN O, Ruotsalainen L, Ikonen E, Nykopp TK, et al
The Paris System for reporting urinary cytology in the follow-up of non-muscle-invasive bladder cancer.
Urol Oncol. 2026;44:173-181.
PubMed
Abstract available

ZHANG H, Li D, Su M, Zheng Z, et al
Lactate-driven H3K18 lactylation promotes cisplatin resistance in bladder cancer via HNRNPF-Parkin mediated mitophagy.
Drug Resist Updat. 2026;88:101435.
PubMed
Abstract available

VULSTEKE C, Ullen A
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply.
N Engl J Med. 2026;394:2383.
PubMed

COLD KM, Vasquez JL
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
N Engl J Med. 2026;394:2382-2383.
PubMed

BALCI S, Tanriverdi R, Nebioglu A, Yildirim DD, et al
Elevated serum Raftlin levels in non-muscle invasive bladder cancer: diagnostic implications and rs690037 genotype analysis.
Rev Assoc Med Bras (1992). 2026;72:e20251628.
PubMed
Abstract available

ZHAO S, Xu S, Cao K, Shi Y, et al
Deficiency of LIMA1 accelerates bladder cancer progression by disrupting PINK1/Parkin-mediated mitophagy.
Cell Death Discov. 2026 Jun 16. doi: 10.1038/s41420-026-03136.
PubMed
Abstract available

SCILIPOTI P, de Angelis M, Thibault C, Slusarczyk A, et al
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.
J Natl Compr Canc Netw. 2026 Jun 16:1-8. doi: 10.6004/jnccn.2026.7014.
PubMed
Abstract available

XIONG Y, Xiao J, Jing L, Bian Y, et al
Machine-learning-assisted artificial olfactory colorimetric sensor array for bladder cancer early detection from urinary volatile organic compounds.
Biosens Bioelectron. 2026;311:118926.
PubMed
Abstract available

LI C, Yang Z, Zhang J, Yan X, et al
Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer.
Clin Transl Oncol. 2026 Jun 16. doi: 10.1007/s12094-026-04460.
PubMed
Abstract available

SHARMA A, Kumar A, Patel P, Kurmi BD, et al
Recent Advances in Intravesical Chemotherapy: Insights into the FDA-Approved Gemcitabine-Releasing TAR-200 System for Bladder Cancer Management.
Anticancer Agents Med Chem. 2026.
PubMed
Abstract available

WANG Z
Spatial profiling in bladder cancer.
Nat Cell Biol. 2026;28:1089.
PubMed

YANG Z, Ma J, Qiang Z, Xie W, et al
ALKBH2 promotes the Warburg effect and bladder cancer progression under hypoxic conditions via the PI3K/AKT pathway.
Clin Exp Med. 2026 Jun 15. doi: 10.1007/s10238-026-02212.
PubMed
Abstract available

WENG M, Wang X, Zhan Y, Guo Y, et al
Machine learning-based identification of basement membrane-related signature to predict recurrence and immunotherapy benefit in bladder cancer.
Immunol Res. 2026;74:59.
PubMed
Abstract available

CITAKKUL I, Temi YB, Baydar E, Sahin E, et al
Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications.
Front Oncol. 2026;16:1820805.
PubMed
Abstract available

LI C, Yang Z, Zhang J, Yan X, et al
ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome.
Front Oncol. 2026;16:1817872.
PubMed
Abstract available

HE Q, Chen Y, Zhang T, Sheng W, et al
TURBT versus RC in T1N0M0 non-urothelial bladder cancer: a population-based study.
Front Oncol. 2026;16:1802962.
PubMed
Abstract available

REICHARD C, Trainer A, Grant K, Asgarisabet P, et al
Analysis of real-world re-induction outcomes with nadofaragene firadenovec in patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer.
Transl Androl Urol. 2026;15:180.
PubMed
Abstract available

LI Y, Liu Y, Xi J, Li X, et al
Super-selective bladder arterial chemotherapy for muscle invasive bladder cancer.
Transl Androl Urol. 2026;15:172.
PubMed
Abstract available

KOGUCHI D, Shiba I, Shiono Y, Matsumoto K, et al
Diagnostic potential of urinary PENK methylation for bladder cancer in patients with hematuria: insights from a prospective and multi-institutional study.
Transl Androl Urol. 2026;15:145.
PubMed

CHEN Y, Zheng J, Li D, Wu Q, et al
Association between prognostic nutritional index (PNI)/Controlling Nutritional Status (CONUT) score and prognosis in patients with bladder cancer: a systematic review and meta-analysis.
Transl Androl Urol. 2026;15:167.
PubMed
Abstract available

WANG T, Wei B
Site-specific heterogeneity in treatment response among patients with metastatic bladder cancer: implications for oligometastatic disease-a retrospective cohort study.
Transl Androl Urol. 2026;15:153.
PubMed
Abstract available

WU Q, Qing X, Gao W
Dietary patterns and knowledge-attitude-practice factors are associated with late recurrence of non-muscle-invasive bladder cancer: a case-control study.
Front Nutr. 2026;13:1842495.
PubMed
Abstract available

JIN M, Cai Z, Bu M, Liu J, et al
From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer.
Front Immunol. 2026;17:1860957.
PubMed
Abstract available

PENG L, Zhang Y, Zhao A, Li R, et al
Benchmarking Large Language Models for Bladder Cancer: Comparative Knowledge Retrieval and Clinical Reasoning of DeepSeek and ChatGPT.
Ann Surg Oncol. 2026 Jun 14. doi: 10.1245/s10434-026-19745.
PubMed
Abstract available

CELLA L, Fasulo V, Uleri A, Piccolini A, et al
Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis.
Sci Rep. 2026 Jun 14. doi: 10.1038/s41598-026-57805.
PubMed
Abstract available

XIAO K, Zhou B, Feng D, Yang S, et al
Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.
J Nanobiotechnology. 2026 Jun 13. doi: 10.1186/s12951-026-04635.
PubMed
Abstract available

HU X, Yang Z, Shi Q, Yu T, et al
A NEK2/ZWINT-NDC80 regulatory axis drives bladder cancer progression and chemoresistance.
Discov Oncol. 2026 Jun 13. doi: 10.1007/s12672-026-05435.
PubMed
Abstract available

WANG C, He S, Zhang B, Zhang S, et al
Development and multicohort validation of an interpretable postoperative model for intravesical recurrence after radical nephroureterectomy in upper tract urothelial carcinoma.
World J Urol. 2026;44:425.
PubMed
Abstract available

GAO S, Zhao X, Jiang P, Liu B, et al
Dual MicroRNA Simultaneous One-Step Profiling via Filler-Mediated Quantum Dot DNA Nanospheres for Bladder Cancer Screening.
ACS Nano. 2026 Jun 13. doi: 10.1021/acsnano.6c03179.
PubMed
Abstract available

TRABELSSI M, Lamy PJ, Daures JP, Perriard F, et al
Xpert(R) bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.
Clin Chim Acta. 2026 Jun 12:121169. doi: 10.1016/j.cca.2026.121169.
PubMed
Abstract available

SUN D, Han C, Li D, Li P, et al
A blood-urine regulatory axis: Tumor-derived factors reprogram urine-derived stem cells via CXCL2/CXCR2/ERK signaling to drive bladder cancer stemness.
Cancer Lett. 2026;656:218675.
PubMed
Abstract available

HE Z, Liu Y, Jiang Q, Hou F, et al
Application Value of Radiomics-Based Machine Learning for Preoperative Risk Stratification of Bladder Cancer: Systematic Review and Meta-Analysis.
J Med Internet Res. 2026;28:e81084.
PubMed
Abstract available

AHMADI P, Deyhimfar R, Haghani I, Mohammadi A, et al
Citalopram enhances cisplatin-induced cytotoxicity in T24 bladder cancer cells: An in vitro study.
Exp Mol Pathol. 2026;147:105056.
PubMed
Abstract available

ANDRZEJCZAK A, Krajewski W, Jaskula E, Chorbinska J, et al
Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome.
Hum Immunol. 2026;87:111783.
PubMed
Abstract available

MUSCO J, Qiao B, Homich A, Kuliszewski MG, et al
Evaluation of Cancer Cases Reported through Inter-Registry Data Exchange in New York State.
J Registry Manag. 2026;53:15-21.
PubMed
Abstract available

SARRIO-SANZ P, Segura-Heras JV, Artes-Artes M, Belda-Ferre M, et al
External Validation of A Decision Tree Model for Predicting Cancer-Specific Mortality After Radical Cystectomy: A Multi-Center Study in South-East Spain.
Arch Esp Urol. 2026;79:567-575.
PubMed
Abstract available

STUCKEY JI, Mertz JA, Wilson JE, Williamson KE, et al
Covalent PPARgamma inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPARgamma/RXRalpha-activated urothelial carcinoma.
Cell Chem Biol. 2026;33:837-847.
PubMed
Abstract available

ZHANG F, An J, Zhao L, Cao Y, et al
Artificial Intelligence-Powered Cystoscopy Diagnostic Support System: Clinical Application of Multiarchitecture Deep Learning Models.
J Endourol. 2026;40:925-934.
PubMed
Abstract available

MARCHETTI KA, Asees A, Bokil AP, Medich M, et al
Survivor-identified barriers and facilitators to acute phase recovery following radical cystectomy.
Urol Oncol. 2026;44:234-242.
PubMed
Abstract available

ABDELSHAFI A, Mohamed T, Mohamed H, Mohammed YA, et al
Hand-sewn versus stapled ileo-ileal anastomosis following radical cystectomy: A systematic review and meta-analysis.
Urol Oncol. 2026;44:215-224.
PubMed
Abstract available

LIU J, Jiang W, Wang X, Azoitei A, et al
CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasion.
Cell Mol Biol Lett. 2026;31:84.
PubMed
Abstract available

YORULMAZ EM, Akin Y, Donmez K, Gorgel SN, et al
Predictive value of the HAS-BLED score in the course of radical cystectomy: A pilot study.
Urol Oncol. 2026;44:297-306.
PubMed
Abstract available

LEON P, Levi LI, Long Depaquit T, Audenet F, et al
Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG.
Fr J Urol. 2026;36:103105.
PubMed
Abstract available

ERIKSSON P, Cotillas EA, Mattsson CA, Zadoroznyj A, et al
Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System.
Mod Pathol. 2026;39:100997.
PubMed
Abstract available

GORAYA DS, Cray M
Partial cystectomy and adjuvant chemotherapy are associated with prolonged survival in dogs and cats with nontrigonal urothelial carcinoma (2010-2014).
J Am Vet Med Assoc. 2026;264:1-7.
PubMed
Abstract available

PERRET RE, Hruby M, Dehner CA, Siegmund SE, et al
Urinary Bladder Leiomyomas: A Clinicopathological Series With Hormone Receptor, HMGA2, 2SC, and Fumarate Hydratase Status Assessment.
Am J Surg Pathol. 2026;50:705-715.
PubMed
Abstract available

SAGAWA T, Ishida T, Jobu K, Sakoda R, et al
Risk factors for intraoperative hypotension associated with the use of oral 5-aminolevulinic acid as a photodynamic diagnostic agent in transurethral resection of bladder tumors: A meta-analysis.
Photodiagnosis Photodyn Ther. 2026;59:105403.
PubMed
Abstract available

INOMATA H, Asatani S, Ikumi N, Uchikawa M, et al
Malignancy-associated Multicentric Reticulohistocytosis Mimicking Dermatomyositis-like Features, with a Significant Ultrasound Finding.
Intern Med. 2025 Nov 6. doi: 10.2169/internalmedicine.6032.
PubMed
Abstract available

KOBAYASHI G, Sekino Y, Hayashi T, Nakahara H, et al
Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance.
Virchows Arch. 2026;488:1227-1242.
PubMed
Abstract available

GONZALGO ML
An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.
Urol Clin North Am. 2026;53:xv-xvi.
PubMed

LOUGHLIN KR
Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?
Urol Clin North Am. 2026;53:xiii-xiv.
PubMed

HARGIS P, Baker H, Wiesen B, Kukreja J, et al
Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.
Urol Clin North Am. 2026;53:509-516.
PubMed
Abstract available

JIANG T, Zhao CC, Liao JC
Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.
Urol Clin North Am. 2026;53:497-508.
PubMed
Abstract available

GUPTA VK, Joyce DD, Wymer KM, Sharma V, et al
Economic Considerations in the Management of Superficial Bladder Cancer.
Urol Clin North Am. 2026;53:487-496.
PubMed
Abstract available

FU MZ, Sykes J, Pfail J, Packiam VT, et al
Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.
Urol Clin North Am. 2026;53:475-486.
PubMed
Abstract available

ZHU S, Washington SL 3rd, Sekar R, Chu CE, et al
Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease.
Urol Clin North Am. 2026;53:463-474.
PubMed
Abstract available

TALLMAN JE, Goh AC
Management of High-Risk Non-Muscle-Invasive Bladder Cancer.
Urol Clin North Am. 2026;53:441-452.
PubMed
Abstract available

NOLAZCO JI, Yim K, Salari K
Molecular and Genetic Insights for Personalized Treatment of Non-Muscle-Invasive Bladder Cancer.
Urol Clin North Am. 2026;53:429-440.
PubMed
Abstract available

WANG B, Isali I, Calaway A, Bukavina L, et al
Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer.
Urol Clin North Am. 2026;53:393-412.
PubMed
Abstract available

CHOU WH, Lechner A, Liu JJ
Role of Enhanced Imaging in Superficial Bladder Cancer Management.
Urol Clin North Am. 2026;53:377-392.
PubMed
Abstract available

HIGGINS MI, Rivera Lopez CA, Lokeshwar SD, Patel SH, et al
Advances in Diagnosis of Non-Muscle-Invasive Bladder Cancer: A Review.
Urol Clin North Am. 2026;53:353-364.
PubMed
Abstract available

AKINSOLA O, Bharadwaj M, Psutka SP
Epidemiology and Risk Factors for Non-Muscle-Invasive Bladder Cancer: Insights into Prevalence, Risk Stratification, and Implications for Early Diagnosis.
Urol Clin North Am. 2026;53:343-352.
PubMed
Abstract available

TAO S, Zhong Y, Ju J, Sun X, et al
Programmable multivalent aptamer-drug conjugates enable stable tumor targeting and enhanced therapy for advanced bladder cancer.
Biomaterials. 2026;335:124396.
PubMed
Abstract available

ABRAHIMI P, Khan JF, Duren-Lubanski A, Cai W, et al
Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.
J Exp Med. 2026;223:e20250699.
PubMed
Abstract available

BARBOSA GR, Dal Col LSB, Bighetto CC, de Godoy MCX, et al
BCG Induces PD-1 Upregulation on Circulating CD8(+) T Cells and IL-6 and IL-8 Secretion In Vitro.
Oncol Res. 2026;34:20.
PubMed
Abstract available

YIN Z, Zhen X, Li H, Duan H, et al
Germinal Center-Like Tertiary Lymphoid Structures Mark Immune Responsiveness and Enable Checkpoint Immunotherapy in Bladder Cancer.
Oncol Res. 2026;34:25.
PubMed
Abstract available

XI Z, Ge H, Zhu J, Yang Q, et al
Comparison of the efficacy of different orthotopic neobladder reconstruction techniques following radical cystectomy for bladder cancer: a network meta-analysis.
Front Oncol. 2026;16:1857787.
PubMed
Abstract available

BILGETEKIN I, Demir N, Eraslan E, Akdagcik Z, et al
Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.
Medicina (Kaunas). 2026;62:1027.
PubMed
Abstract available

KLIMCZAK A, Krawczenko A, Stamnitz S, Bielawska-Pohl A, et al
Immunotoxin WPD101a as a Potential Drug Candidate for Targeted Therapy in Muscle Invasive Bladder Cancer Expressing IL-13Ralpha2-In Vitro Study.
Int J Mol Sci. 2026;27:5566.
PubMed
Abstract available

BAEK SW, Yoon SY, Kim SK, Leem SH, et al
Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment.
Int J Mol Sci. 2026;27:5152.
PubMed
Abstract available

HUANG A, Waltzer WC, Hung M, Darras FS, et al
Identification of circCIAO1(5) and circMALAT1 as Novel Potential Biomarkers for Bladder Cancer Monitoring Based on the Binding to miR-101-3p.
Cancers (Basel). 2026;18:1968.
PubMed
Abstract available

FENG T, Jiang L, Zhuang J, Cai L, et al
PD-L1+ CTCs Are Associated with Adverse Pathological Features and Unfavorable Prognosis in Bladder Cancer.
Diagnostics (Basel). 2026;16:1776.
PubMed
Abstract available

CHEN J, An Y, Tong A, Kang S, et al
Bacteroides fragilis toxin promotes gall bladder cancer in mice.
Nat Microbiol. 2026 Jun 25. doi: 10.1038/s41564-026-02404.
PubMed
Abstract available

CHEN L, Liang C
Can manual gemcitabine instillation or tumor microenvironment-based selection enhance the efficacy of TAR-200 in bladder cancer?
Transl Oncol. 2026;71:102875.
PubMed
Abstract available

CHENG K, Zhang HB, Xie HR, Wang L, et al
PRDX1 as a novel urinary biomarker for bladder cancer: Development of an integrated fiber optic sensing platform.
Talanta. 2026;311:130162.
PubMed
Abstract available

WEI L, Guo Y, Hao Y, Ji L, et al
FASN Promotes Malignant Progression of Bladder Cancer by Regulating Lipid Metabolism via the ERK/PPAR Pathway.
Cell Biochem Biophys. 2026 Jun 25. doi: 10.1007/s12013-026-02104.
PubMed
Abstract available

SINGH R, Up S, Garg M
Association of Epithelial-to-Mesenchymal Transition Related Markers With Clinical Outcome in Non-Muscle Invasive and Muscle Invasive Bladder Cancer Patients.
Cell Biochem Biophys. 2026 Jun 25. doi: 10.1007/s12013-026-02106.
PubMed
Abstract available

PEREIRA M, Vale N
Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells.
Cells. 2026;15:1045.
PubMed
Abstract available

SCILIPOTI P, Slusarczyk A, Thibault C, Domanski P, et al
Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.
Eur Urol Oncol. 2026 Jun 25:S2588-9311(26)00174.
PubMed
Abstract available

SLUSARCZYK A, Moschini M, Krajewski W, Scilipoti P, et al
Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis.
Eur Urol Oncol. 2026 Jun 25:S2588-9311(26)00173.
PubMed
Abstract available

ZHANG Q, Zhang Q, Guo C, Peng C, et al
scTumorDrug: predicting cell-type-specific drug responses for heterogeneous tumors.
Brief Bioinform. 2026;27:bbag337.
PubMed
Abstract available

PENG M, Shen L, Song D, Wen L, et al
Diagnostic Value of Spectral CT-Derived Extracellular Volume Fraction in the Early Detection of Sigmoid Colon Metastasis from Bladder Cancer: A Case Report.
Surg Case Rep. 2026;12:26-0147.
PubMed
Abstract available

JIN ZR, Dong CY, Li YJ, Zou Y, et al
Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH-Bladder Cancer: A Case Report.
Clin Case Rep. 2026;14:e72855.
PubMed
Abstract available

ZHANG S, Zhang H, Dong X, Qi Z, et al
Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer.
Front Immunol. 2026;17:1866469.
PubMed
Abstract available

HAQ F, Chinchankar S, Ambite I, Ahmadi S, et al
Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue.
Cancer Metab. 2026;14:21.
PubMed
Abstract available

CHEN X, Tang Q, Wang Y, Zhang J, et al
LncRNA ACTA2-AS1 acts as a bladder cancer prognostic biomarker and blocks malignant advance via miR-148b-3p/DNAJB4.
World J Surg Oncol. 2026 Jun 23. doi: 10.1186/s12957-026-04447.
PubMed
Abstract available

LI X, Yang J, Cha J, Xie H, et al
Multi-omics integration and clinical validation identify CKAP2 as a diagnostic biomarker for bladder cancer.
World J Surg Oncol. 2026 Jun 23. doi: 10.1186/s12957-026-04464.
PubMed
Abstract available

GRANDE E, Sibai M, Grases D, Andrada E, et al
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.
Cell Rep Med. 2026 Jun 23:102878. doi: 10.1016/j.xcrm.2026.102878.
PubMed
Abstract available

PINHEIRO LCL, de Souza Martins MAF, Turim MFV, da Silva IM, et al
Interplay between CDH1 polymorphisms, haplotypes, and genomic repetitive elements in urothelial bladder cancer prognosis.
Mol Biol Rep. 2026;53:990.
PubMed
Abstract available

MARI A, Lambertini L, Albisinni S, Contieri R, et al
The old standard still holds up: reading CREST, POTOMAC, and ALBAN in BCG-naive high-risk non-muscle-invasive bladder cancer.
Minerva Urol Nephrol. 2026 Jun 23. doi: 10.23736/S2724-6051.26.07132.
PubMed

LEDDEROSE S, Schwenke J, Eismann L, Rodler S, et al
Ectonucleotidases CD39 and CD73 expression levels are independent and inverse predictors of survival in muscle-invasive bladder cancer.
J Pathol Clin Res. 2026;12:e70102.
PubMed
Abstract available

LI B, Yang Z, Pei Y, Wang Y, et al
Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy.
Cancer Med. 2026;15:e71859.
PubMed
Abstract available

MA L, Zhang YY, Wang L, Yue FK, et al
[MiR-527 targeting Bcl-2 inhibits migration and promotes apoptosis in bladder urothelial cell carcinoma].
Zhonghua Zhong Liu Za Zhi. 2026;48:793-801.
PubMed
Abstract available

YU Z, Zhang J, Wang Z, Wei S, et al
H3K18la-PSMG1 Axis in Bladder Cancer Progression: Curcumin as a Therapeutic Candidate.
Int J Biol Sci. 2026;22:5953-5968.
PubMed
Abstract available

ZHANG K, Ren Y
Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Onco Targets Ther. 2026;19:614003.
PubMed
Abstract available

WU J, Liang P, He Y, Zhang M, et al
VSIG2 is associated with an immune-cold microenvironment and reduced response to PD-1 blockade in bladder cancer.
Front Cell Infect Microbiol. 2026;16:1859986.
PubMed
Abstract available

LINEHAN J, Agarwal PK, Penny X, Kates M, et al
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Open Sci. 2026;89:77-88.
PubMed
Abstract available

TONG Z, Yu T, Li Z, Zhang F, et al
Ultra-sensitive urine DNA methylation test enables early and accurate detection of bladder cancer.
Epigenomics. 2026;18:709-721.
PubMed
Abstract available

AYDOGDU C, Wang B, McSweeney S, Pieretti A, et al
Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.
Ann Surg Oncol. 2026 Jun 21. doi: 10.1245/s10434-026-20022.
PubMed
Abstract available

XU H, Wu J, Bai Y, Qin J, et al
Bio-inspired indocyanine green supramolecular assemblies for high-contrast NIR-II imaging and cooperative dual-targeting of bladder cancer.
Biomaterials. 2026;335:124397.
PubMed
Abstract available

PARK IW, Uk PM, Lim B, Jeong IG, et al
Nephroureterectomy with ileal cuff for upper tract recurrence after radical cystectomy: oncologic and survival outcomes.
World J Urol. 2026;44:443.
PubMed
Abstract available

PARIZI MK, D'Andrea D, Pradere B, Teoh JY, et al
Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients.
Eur Urol Oncol. 2026 Jun 20:S2588-9311(26)00168.
PubMed
Abstract available

JACKSON-SPENCE F, Aspden D, Chauhan V, Diaz S, et al
Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy.
Cancer Med. 2026;15:e71873.
PubMed
Abstract available

ROVIELLO G, Gambale E, Giorgione R, Basso U, et al
Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.
Sci Rep. 2026 Jun 19. doi: 10.1038/s41598-026-58269.
PubMed
Abstract available

HOF JP, Galesloot TE, Aben KKH, Bryan RT, et al
Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.
Cancer Genet. 2026;306-307:106-115.
PubMed
Abstract available

ZAHRAN AA, Shokeir AA, Serria MS, Awadalla A, et al
Predictive value of toll-like receptors, myeloid differentiation factor 88, and nuclear factor kappa-B regarding the response to Bacillus Calmette-Guerin intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: A controlled
Urol Oncol. 2026;44:195-210.
PubMed
Abstract available

ROSENBERG JE, O'Donnell PH, Petrylak DP, Flaig TW, et al
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
ESMO Open. 2026;11:107700.
PubMed
Abstract available

HEIDENREICH A
[Non-muscle-invasive urothelial carcinoma of the bladder: time for a de-escalation of treatment and aftercare].
Urologie. 2026;65:710-718.
PubMed
Abstract available

ZOCK JP, Rijs KJ, Peters S, Vlaanderen JJ, et al
Associations between occupational exposure to chromium (VI) and cancers of the oral cavity, small intestine, pancreas, prostate and urinary bladder: systematic review and meta-analyses.
Occup Environ Med. 2026;83:162-169.
PubMed
Abstract available

RAUCH S, Lange F, Hartmann A, Eckstein M, et al
[Diagnostic and predictive molecular pathology of urothelial carcinoma : Current status and outlook for the future].
Pathologie (Heidelb). 2026;47:254-261.
PubMed
Abstract available

SMEULDERS N, Gaze MN, Guerin F, Rogers T, et al
Surgical nodal staging in rhabdomyosarcoma of the bladder and/or prostate with or without nodal or metastatic spread. A report from the European Paediatric Soft-Tissue Sarcoma Study Group (EpSSG).
J Pediatr Surg. 2026;61:163162.
PubMed
Abstract available

BEN KRIDIS W, Khanfir A
Adjuvant PD-1 Inhibitors After Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Phase 3 Trials.
Urol Pract. 2026;13:450-458.
PubMed
Abstract available

COVOTTA M, Claroni C, Ceccarelli V, Morettini L, et al
Prediction of postoperative complications after robotic radical cystectomy: comparison of four preoperative scores.
J Robot Surg. 2025;20:118.
PubMed
Abstract available

BDIOUI A, Mahmoudi A, Lajmi Z, Krifa M, et al
Prognostic value of tumor budding in muscle-invasive urothelial carcinoma of the bladder.
J Egypt Natl Canc Inst. 2025;37:76.
PubMed
Abstract available

KHALIL Y, Sun YQ, Mai XM
Nonexercise estimated cardiorespiratory fitness in relation to incidence of urinary tract, bladder and kidney cancer in the HUNT study.
Sci Rep. 2025;15:45231.
PubMed
Abstract available

PLYMOTH M, C CW, Harvey R, Crighton T, et al
Disseminated Bacillus Calmette-Guerin infection following concurrent intravesical BCG therapy and immune checkpoint inhibitior therapy: a case report.
BMC Infect Dis. 2025;25:1575.
PubMed
Abstract available

DAGNINO F, Beatrici E, Qian Z, Stelzl D, et al
Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes.
World J Urol. 2025;43:647.
PubMed
Abstract available

CHEN H, Weng Y, Zheng D, Li T, et al
Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine.
J Adv Res. 2026;85:837-852.
PubMed
Abstract available

GOBINET L, Klein C, Brunelle S, Illy M, et al
Can bladder MRI avoid systematic second TURBT for patients with high-risk NMIBC?
World J Urol. 2025;43:612.
PubMed
Abstract available

BOTROUS S, Elmaghraby A, Achy SE, Mustafa Y, et al
Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models.
BMC Biotechnol. 2025;25:102.
PubMed
Abstract available

LEE C, Nam W, Kim CW, Yoon YS, et al
Clinical outcomes of neobladder or augmentation after cystectomy in locally advanced colorectal cancer involving urinary tract: case series.
BMC Urol. 2025;25:221.
PubMed
Abstract available

KLATTE T, Hofbauer SL, Ebert J, Ecke TH, et al
Real-world Patterns and Trends of Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer: Insights from a Large Prospective German Cohort.
Anticancer Res. 2026;46:3333-3342.
PubMed
Abstract available

SABBADINI P, Paganoni E, Galeasso L, Depetris I, et al
Basaloid Urothelial Carcinoma Presenting With Paraneoplastic Hypercalcemia and Leukocytosis: A Case Report and Literature Review.
Anticancer Res. 2026;46:3517-3522.
PubMed
Abstract available

ABOU CHAKRA M, Alsamarah I, Hougen HY, Zakharia Y, et al
Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.
BJU Int. 2026 May 28. doi: 10.1111/bju.70319.
PubMed
Abstract available

UROLAGIN D, Sowmya BA, Kavyashree MV
Comment on 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
BJU Int. 2026 Jun 10. doi: 10.1111/bju.70296.
PubMed

VAN HATTUM JW, Remmelink MJ, Oddens JR, de Reijke TM, et al
Response letter 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
BJU Int. 2026 Jun 9. doi: 10.1111/bju.70295.
PubMed

NOLAZCO JI, Melnick KR, Lee RJ, Efstathiou JA, et al
Alternatives to radical cystectomy: a bladder-sparing approach in appropriately selected patients.
BJU Int. 2026;138:22-32.
PubMed
Abstract available

ORECCHIA L, Gerardi M, Colalillo G, Leonardis F, et al
Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial.
BJU Int. 2026;138:92-99.
PubMed
Abstract available

MURRAY BO, Gao J, Pasquina-Lemonche L, Swarbrick K, et al
An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.
Br J Cancer. 2026 Jun 2. doi: 10.1038/s41416-026-03476.
PubMed
Abstract available

MEHTA S, Weinfeld M, Hobeika C, Reizine N, et al
The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.
Cancer. 2026;132:e70448.
PubMed
Abstract available

HUANG S, Jia K, Liang S, Ma B, et al
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel.
Cancer. 2026;132:e70498.
PubMed
Abstract available

ROELS J, Ghaedi H, Kancherla J, Yang Y, et al
The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1-Resistant Cancer.
Cancer Res. 2026;86:2592-2605.
PubMed
Abstract available

NEUENSCHWANDER A, Uleri A, Grobet-Jeandin E, Contieri R, et al
Impact of a multidisciplinary approach on outcomes in urothelial carcinoma.
Curr Opin Urol. 2026;36:446-452.
PubMed
Abstract available

MAIORANO BA, Dizman N, Necchi A
Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma.
Eur Urol. 2026;89:479-482.
PubMed
Abstract available

BASIN MF, Daneshmand S
Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer.
Eur Urol. 2026 Jun 17:S0302-2838(26)02171-8. doi: 10.1016/j.eururo.2026.
PubMed
Abstract available

MERTENS LS, Mellema JJ, Sridhar S, van der Heijden MS, et al
Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.
Eur Urol. 2026 Jun 17:S0302-2838(26)02186-X. doi: 10.1016/j.eururo.2026.
PubMed

NISHIMURA N, Miyake M, Iwao T, Oda Y, et al
Sarcopenia Weakens the Benefit of Bacillus Calmette-Guerin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study.
Int J Urol. 2026;33:e70526.
PubMed
Abstract available

KOBAYASHI G, Sekino Y, Miyamoto S, Kobatake K, et al
Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset.
Int J Urol. 2026;33:e70538.
PubMed
Abstract available

ENDO Y, Sakura Y, Kaneko G, Hayakawa N, et al
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter Study.
Int J Urol. 2026;33:e70523.
PubMed
Abstract available

IGARASHI A, Kinoshita T, Fujita M, Obayashi R, et al
Intraoperative Hypotension During Photodynamic Diagnosis-Guided TURBT Under Spinal Anesthesia: A Propensity Score-Matched and Logistic Regression Analysis.
Int J Urol. 2026;33:e70540.
PubMed
Abstract available

MCMASTER T, Hoskin G, Homewood D, Attwell-Heap A, et al
A comparative analysis of variant histology and urothelial bladder cancer following radical cystectomy.
Int Urol Nephrol. 2026 Jun 10. doi: 10.1007/s11255-026-05234.
PubMed
Abstract available

CONTIERI R, Jannello LMI, Vartolomei MD, Roth B, et al
Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis.
Int Urol Nephrol. 2026;58:2463-2471.
PubMed
Abstract available

DENG S, Jiang R, Wu S, Xiao Y, et al
Bladder tumors in patients initially diagnosed with interstitial cystitis: a ten-year retrospective study.
Int Urol Nephrol. 2026;58:2503-2511.
PubMed
Abstract available

SANDBERG M, Thole D, Bissette R, Wolff D, et al
Comparing benign to malignant cystectomy: complications, emergency department utilization, readmissions, and socioeconomic status.
Int Urol Nephrol. 2026;58:2429-2436.
PubMed
Abstract available

CATHOMAS R, Petrausch U, Hayoz S, Spahn M, et al
Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.
J Clin Oncol. 2026 May 29:101200JCO2600845. doi: 10.1200/JCO-26-00845.
PubMed
Abstract available

NECCHI A, de Jong JJ, Maiorano BA, Proudfoot JA, et al
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.
J Clin Oncol. 2026 May 31:JCO2600142. doi: 10.1200/JCO-26-00142.
PubMed
Abstract available

PRASAD S
Reply: UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results from the Phase 3 ENVISION Trial.
J Urol. 2026 Jun 2:101097JU0000000000005128. doi: 10.1097/JU.0000000000005128.
PubMed

JOYCE DD, Sharma V, Boorjian SA
With great cost comes great responsibility: who will own the rising costs of bladder cancer care?
J Urol. 2026 Jun 26:101097JU0000000000005185. doi: 10.1097/JU.0000000000005185.
PubMed

ST-LAURENT MP, Din S, Moryousef J, Lajkosz K, et al
Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged
J Urol. 2026 Jun 24:101097JU0000000000005183. doi: 10.1097/JU.0000000000005183.
PubMed
Abstract available

EFENDIOGLU F, Ozcan C, Turkmen V, Ugurlu O, et al
Effect of Catheter Type and Size on Patient Comfort and Complications in Intravesical Bacillus Calmette-Guerin and Chemotherapy Administration: A Randomized Prospective Pilot Study.
Urology. 2026;212:51-56.
PubMed
Abstract available

NATHAN KK, Duke Herrell S, Westerman MB, Bjurlin MA, et al
From Lichtleiter to Laser: A 200-Year Odyssey of Transurethral Resection of Bladder Tumors.
Urology. 2026;212:116-121.
PubMed
Abstract available

MALSHY K, Lim K, Jia Y, Guo W, et al
Utilization and Costs Among Bladder Cancer, Other Cancer, and Non-Cancer Populations in the United States.
Urology. 2026 Jun 14:S0090-4295(26)00373-0. doi: 10.1016/j.urology.2026.
PubMed
Abstract available

ALMOHTASIB J, Scire E, Kaul S, Fleishman A, et al
Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.
Urology. 2026 Jun 26:S0090-4295(26)00420-6. doi: 10.1016/j.urology.2026.
PubMed
Abstract available

CHEN C, Liu X, Xu A, Jiang N, et al
Transcriptomic analysis of genes in bladder cancer patients with resistance to neoadjuvant chemoimmunotherapy.
BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16165.
PubMed
Abstract available

WU Q, Lu P, Zhang X, Qing X, et al
Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review.
BMC Cancer. 2026;26:680.
PubMed
Abstract available

HU P, Wang C, Zeng X, Jin S, et al
The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of bladder cancer patients: a systematic review and meta-analysis.
BMC Cancer. 2026 Jun 13. doi: 10.1186/s12885-026-16326.
PubMed
Abstract available

RIZZO A, Ciccimarra F, de Casio Zequi S, Bove S, et al
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2(EV) project.
BMC Cancer. 2026;26:756.
PubMed
Abstract available

YI L, Ma Z, Zhang J, Zhan Y, et al
A stratified urine-based molecular diagnostic and prognostic model for non-muscle-invasive bladder cancer management.
BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16361.
PubMed
Abstract available

ALTIN E, Dogan C, Arslan AI, Topkac EC, et al
ELF-3 and TSC-1 as potential markers of recurrence in low-risk non-muscle-invasive bladder cancer.
BMC Cancer. 2026 Jun 20. doi: 10.1186/s12885-026-16314.
PubMed
Abstract available

ZHANG J, Cheng X, Huang C, Xu Y, et al
The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin/POU4F2 to detect bladder carcinoma.
BMC Cancer. 2025;25:1460.
PubMed
Abstract available

RAHATIJAFARABAD B, Poorkhani A, Esfandiari F, Sedaghat S, et al
Trends in urinary tract cancer incidence in Golestan province, Iran: a 16-year population-based study.
BMC Cancer. 2025;25:1227.
PubMed
Abstract available

CHEN X, Wang Z, Rong Y, Zhu Z, et al
Elevated ICAM5 as a promising predictor of poor prognosis in bladder cancer via EMT, immune microenvironment, and therapy resistance.
PLoS One. 2026;21:e0347623.
PubMed
Abstract available

ZHANG Q, He C, Hong Y, Huang T, et al
EP300 promotes bladder cancer cell migration through SNAI2.
PLoS One. 2026;21:e0347209.
PubMed
Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum

;